Strata Critical Medical (SRTA) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.12

Estimate

-$0.02

Surprise

-500.0%

Revenue (period 2026-06-30)

$72.5M

Score today

6.3/10

Revenue source: xbrl.

Strata Critical Medical (SRTA) reported a wider loss than forecast — diluted EPS of -$0.12 against the -$0.02 estimate (a 500.0% shortfall).

TrendMatrix currently rates SRTA Sell at 6.3/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -500.0% surprise compares with a -322.0% four-quarter average. Next scheduled report: 2026-11-09.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$6.24

Price target

$8.13

Stop

$5.80

Upside to target

+30.3%

Reward-to-risk

2.0:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Care Facilities

Market cap

$552.0M

52-week range

$3.85–$6.50

Off 52-week high

4.0%

RSI (14)

68

Volume vs avg

0.91×

Score today

6.3/10